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Abstract
The incidence and mortality of pancreatic adenocarcinoma are nearly coincident having a five-year
survival of less than 5%. Enormous advances have been made in our knowledge of the molecular
alterations commonly present in ductal cancer and other pancreatic malignancies. One significant
outcome of these studies is the recognition that common ductal cancers have a distinct molecular
fingerprint compared to other nonductal or endocrine tumors. Ductal carcinomas typically show
alteration of K-ras, p53, p16INK4, DPC4 and FHIT, while other pancreatic tumor types show different
aberrations. Among those tumors arising from the exocrine pancreas, only ampullary cancers have
a molecular fingerprint that may involve some of the same genes most frequently altered in
common ductal cancers. Significant molecular heterogeneity also exists among pancreatic
endocrine tumors. Nonfunctioning pancreatic endocrine tumors have frequent mutations in MEN-
1 and may be further subdivided into two clinically relevant subgroups based on the amount of
chromosomal alterations. The present review will provide a brief overview of the genetic
alterations that have been identified in the various subgroups of pancreatic tumors. These results
have important implications for the development of genetic screening tests, early diagnosis, and
prognostic genetic markers.
Review
Pancreatic cancer incidence and mortality virtually coin-
cide having a five-year survival of less than 5%. Surgical
intervention is possible in only about 10% of cases and
adjuvant therapies are virtually ineffective. An improved
understanding of pancreas cancer genetics is the only
means to provide new markers for early diagnosis and to
identify potential targets for therapeutic intervention. Mo-
lecular analyses of pancreatic cancer have been hindered
by the low cancer cellularity of this neoplasm, due to the
characteristic host desmoplastic reaction. This has been
overcome in large part to the application of various en-
richment techniques such as xenografting, cryostat-en-
richment, and laser capture microdissection of primary
lesions. Consequently, enormous advances have recently
been made in our knowledge of the molecular alterations
in commonly present pancreatic ductal adenocarcinoma.
Not unsurprisingly, as for other cancers, both activation of
oncogenes and inactivation of tumor suppressor genes
play key roles in pancreatic cancer.
Ductal adenocarcinoma is by far the most common pan-
creatic neoplasm, comprising around 90% of all pancreat-
ic malignancies. However, other types of tumors arise
from both the exocrine or endocrine cellular components.
A dissection of the assortment of genetic anomalies has al-
lowed for the important distinction at the molecular level
that common ductal carcinoma has a distinct molecular
fingerprint compared to other nonductal exocrine or en-
docrine tumors. Moreover, while endocrine tumors have
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been traditionally grouped together as a single class of ne-
oplasms, significant molecular heterogeneity exists even
among this broad faction of tumors. Accordingly, the
present review will give a brief overview of the genetic al-
terations that have been identified in the various sub-
groups of pancreatic lesions. The known chromosomal/
genetic alterations commonly present in pancreatic tu-
mors are presented in Table 1.
Ductal adenocarcinoma
At present, the well-established molecular events that
have been correlated with the pathogenesis of ductal neo-
plasms include activation of the K-ras oncogene in about
80% of cases and inactivation of the tumor suppressor
genes p16INK4a, p53, and DPC4 in about virtually all, 60%,
and 50% of primary cancers, respectively [1,2]. In addi-
tion, anomalies in FHIT gene expression have been shown
in about half of cases [3]. The coexistent inactivation of
p16, p53, and DPC4 is also common [1,2]. Telomerase ac-
tivity has been detected in up to 95% of cases and unde-
tectable in benign tumors [4].
The inactivation of additional genes has been implicated
in pancreatic cancer albeit at lower frequencies. These in-
clude MKK4, part of a stress-response signaling pathway,
in 4% of cases; a TGF-beta receptor in 1% of cases;BRCA2
in nearly 7% and LKB1/STK11 in about 5% of cases [5–9].
Microsatellite instability of the type associated with muta-
tion of DNA repair genes has been observed in a small
proportion of ductal cancers and has been associated with
an improved prognosis [10,11]. Microsatellite instability
has also been found in a limited number of the rare med-
ullary carcinoma [12].
The knowledge of gene alterations involved in transfor-
mation has also allowed for the identification and classi-
fication of morphological precursor lesions (PanIN),
which has permitted the construction of a model for dis-
ease progression [13]. Whereas mutation of K-ras  and
overexpression of Her2/neu are initial events, alteration of
p16 has been associated with progression of malignancy.
It is also apparent that mutation of p53 and DPC4 are
events that occur relatively late in the transformation
process [14,15]. These are not trivial points as a model of
genetic progression forms the basis of our understanding
of cancer transformation and progression of malignancy.
Telomere shortening has also been recently observed to be
a frequent event in PanINs, which is highly suggestive that
this genetic event plays an early role in neoplastic progres-
sion [16]. The fact that p16 is also methylated in PanINs
gives further support to this idea [17,18]. Such a model
has important implications for the development of genet-
ic screening tests, early diagnosis, prognostic genetic
markers and chemoprevention.
It is becoming increasingly apparent that the role of DNA
methylation has in pancreatic cancer. About 50% of all
human genes have 5' CpG islands, which are typically as-
sociated with the 5' regulatory regions of genes. Methyla-
tion at these 5' CpG islands generally inactivates gene
expression, while demethylation has the opposite effect.
While part of normal developmental and aging processes,
when deregulated, these events may also inactivate tumor
suppressor genes or activate otherwise silenced genes. Pro-
moter methylation is implicated in the transcriptional si-
lencing of several tumor suppressor and mismatch repair
genes (e.g., p16, Rb, VHL, hMLH1) in many cancers. In
pancreatic cancer, de novo methylation of a number of
genes has been reported [19]. Among these, ppENK, a gene
with known growth suppressive properties, has been asso-
ciated with transcriptional silencing in over 90% of cases
[20]. Larger pancreatic cancers and those from older pa-
tients possessed more methylated loci compared to small-
er tumors and those from younger patients. The
identification of larger numbers of genes controlled by
methylation has been undertaken and should provide a
larger number of genetic targets, which will be invaluable
for diagnosis, prognosis, and therapy [19,20].
The quantitative and comprehensive analysis of cellular
gene expression profiles has been performed using serial
analysis of gene expression (SAGE) and DNA microarrays.
Table 1: Summary of Known Chromosomal/Gene Alterations in Pancreatic Tumors
Chromosomal Gene
Ductal 9p, 17p, 18q K-ras, p53, p16, DPC4
Acinar 1p, 4q, 17p APC/β-catenin
Serous Cystic 3p, 10q VHL
Mucinous Cystic undescribed p53,DPC4
IPMT undescribed K-ras
Solid papillary undescribed β-catenin
Ampullary undescribed K-ras, p53, p16, DPC4
NF-PET 6q, 11, 20q, 21 MEN1Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/7
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These expression profiling studies and SAGE studies have
already allowed for the identification of several candidate
genes which may be useful as potential diagnostic/prog-
nostic markers as well as therapeutic targets [21–31].
Nonetheless, these studies are far from complete and are
just beginning to unravel the enormous complexities that
underlie pancreatic cancer.
One hallmark of pancreatic ductal cancers is the character-
istic host desmoplastic reaction that has hindered genetic
studies on this neoplasm. Several reports have examined
in detail this interaction. Recently, the stromal reaction
has been investigated by DNA array analysis using normal
pancreas, bulk pancreatic tumor tissues and pancreatic tu-
mor aspirates that contain more than 95% tumor cells. In
fact, fine needle aspiration of cancer provides a fast and ef-
ficient way of obtaining samples highly enriched in tumor
cells with sufficient yields of RNA. Altered expression of
genes not previously associated with pancreatic adenocar-
cinoma was found, including rac1, GLG1, NEDD5, RPL-
13a, RPS9 and members of the Wnt5A gene family [25].
Little is known about the genetic factors responsible for
familial pancreatic cancer, although familial aggregation
and genetic susceptibility may play a role in as many as
10% of pancreatic ductal adenocarcinomas. Germline
mutations have been reported in BRCA2  and  p16, al-
though these account for only a fraction of cases [32–34].
Other tumors arising from the exocrine pancreas
Less is known about the molecular abnormalities in the
more rare epithelial neoplasms of the exocrine pancreas.
This heterogeneous group of neoplasms includes tumor
entities with distinct clinicopathologic and prognostic
features that comprise the acinar cell carcinomas, the se-
rous cystic tumors, mucinous cystic tumors, intraductal
papillary-mucinous tumors, the solid-pseudopapillary tu-
mors, and ampullary cancers. In general, the available
data suggests that these neoplasms have molecular patho-
genetic pathways that are different from those occurring
in common pancreatic adenocarcinoma.
Acinar cancers
In these neoplasms, mutations in K-ras are exceedingly
rare and p53 mutations have not been found [2,35]. Like-
wise, alterations in p16 or DPC4 are absent [2]. A recently
performed genome wide allelotyping of these tumors has
shown a high degree of allelic loss [36]. Chromosomes
1p, 4q, and 17p show LOH in >70% of cases and chromo-
somes 11q, 13q, 15q, and 16q show allelic loss in 60–
70% of cases. The resulting allelotype of acinar carcinoma
is markedly different from that of either ductal or endo-
crine tumors of the pancreas and the involvement of chro-
mosome 4q and 16q seems characteristic of this tumor
type. Interestingly, alterations in the APC/β-catenin path-
way have been found in 4 of 17 cases of acinar carcinoma
studied [37].
Serous cystic tumors
These lesions may present as sporadic forms or in associ-
ation with von Hippel Lindau syndrome. A molecular
characterization of these tumors consisting in genome-
wide allelic loss analysis, assessment of microsatellite in-
stability, and mutational analysis of the VHL, K-ras and
p53 genes has been recently reported [38]. While no case
showed microsatellite instability, a relatively low fraction-
al allelic loss of 0.08 was found. The allelotype demon-
strated that losses on chromosome 10q were the most
frequent event, observed in about 50% of cases, followed
by allelic losses on chromosome 3p, found in almost 40%
of cases. The VHL gene was found to possess somatic inac-
tivating mutations in two of nine (22%) cases analyzed,
while no mutations were found in either K-ras or p53.
Thus, involvement of chromosome 10q is characteristic of
serous cystic tumors and the VHL gene is involved in a
subset of sporadic cases.
Mucinous cystic tumors
K-ras mutations have been reported in a variable propor-
tions among mucinous cystic tumors. The expression of
p53 and Dpc4 has been reported as frequently altered and
is likely to be related to progression in this malignancy
[39,40].
Intraductal papillary-mucinous tumors
To date, K-ras mutations have been found in intraductal
papillary-mucinous tumors (IPMT) at varying frequency,
while no alterations of p16, p53 or DPC4 have been found
[2,41]. There is also a low frequency of LOH found on
chromosomal arms 9p, 17p, and 18q further substantiat-
ing the supposition that these are entities separate from
ductal cancers. IPMT have also been recently studied by
cDNA microarray analysis, which led to the observation
that several genes are differentially expressed both in IP-
MTs and pancreatic carcinomas. This suggests that they
may be involved at an early stage of pancreatic carcino-
genesis [42].
Solid-pseudopapillary tumors
These neoplasms are generally low-grade malignancies
primarily affecting girls and young women and character-
istically show progesterone receptor immunostaining
[39]. Neither alterations in ras-family genes, p53 gene/
protein, p16, or DPC4 have been found. Similarly, allelic
losses on chromosomal arms 9p, 17p, or 18q have not
been detected in these tumors [2]. Immunohistochemis-
try showed positive staining for Dpc4, as expected from
microsatellite analysis [2]. Recently, it has been shown
that the vast majority of cases harbor mutations in β-cat-
enin [43,44].Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/7
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Ampullary cancers
Compared with other exocrine pancreatic tumors, only
ampullary cancers have a molecular fingerprint that may
involve some of the same genes most frequently altered in
common ductal cancers. In fact, alterations have been
found in K-ras, p53, p16, and DPC4, with p53 inactivation
being the most frequent event (60%) [45]. K-ras muta-
tions are seen in about one-half of cases [46,47]. Inactiva-
tion of DPC4 was found in about 50% of cases as shown
by negative staining for the protein by immunohisto-
chemistry [2]. There is however, no correlation between
the lack of expression of Dpc4 and survival [48]. However,
allelic losses on chromosomal arm 17p (63%) have been
previously found to be an independent prognostic factor
among ampullary cancers at the same stage [49]. Taken to-
gether, this data reinforces the hypothesis that ductal tu-
mors and ampullary cancers share common molecular
pathways related to tumorigenesis and, possibly, progres-
sion of malignancy. Mutations in the APC gene have also
been found in a proportion of these cancers [50]. Unlike
ductal carcinoma however, about 10% of ampullary tu-
mors show microsatellite instability, a feature that signifi-
cantly correlates with increased survival [51].
Pancreatic endocrine tumors
Much progress has been made in the understanding of
pancreatic endocrine tumors (PETs). Nonfunctioning
(NF) PETs do not lead to clinical symptoms due to hor-
monal hypersecretion by the neoplasm, while functioning
PETs are in fact a heterogeneous group of malignancies
that give rise to clinical symptoms due to hormonal hy-
persecretion by the neoplasm. To date, nine distinct func-
tional PETs have been designated, although detailed
molecular studies of these neoplasms are lacking, in con-
trast to NF-PETs.
In reality, the elucidation of the molecular events in-
volved in PET carcinogenesis has in part been hindered by
the fact that these neoplasms have been considered a sin-
gle disease entity. The emergence of novel molecular char-
acterization strategies has made it apparent however that
these lesions exhibit diverse molecular fingerprints (see
[52] for review). Studies involving the genes most fre-
quently altered in exocrine pancreatic tumors (i.e., p53, K-
ras, p16 and DPC4) have confirmed that PETs arise from
distinctly different molecular pathways and are unrelated
to ductal cancers [2]. Mutations in K-ras and p53 are ex-
tremely rare and p16 and DPC4 alterations are virtually
absent [2,53]. The rare involvement of Dpc4 in either pri-
mary or metastatic PETs has also been confirmed by im-
munohistochemistry [54], but reinforces the fact that
these tumors have pathogenetic pathways distinct from
ductal adenocarcinoma.
To date, mutation of MEN-1 is the most common genetic
alteration found in PETs, but with markedly different fre-
quencies among insulinomas (7%), other functioning
PETs (44–67%) NF-PETs (27%), giving the first genetic
clue that PETs might be divided into the three above-men-
tioned subgroups (see [55]). The fact that mutations in
MEN-1 are found in NF-PETs is not surprising when con-
sidering that NF-PETs are fairly common in MEN1 pa-
tients. Mutations in VHL are extremely rare in sporadic
PETs [55,56].
A recent high resolution allelotype for NF-PET has sug-
gested the existence of two subgroups: those showing fre-
quent, large allelic deletions and those showing a small
number of random losses, designated high or low FAL, re-
spectively [57]. Chromosomes 6q and 11, 20q, and 21
show frequent LOH. The allelotype of NF-PET is moreover
markedly different from that of ductal, acinar, or serous
tumors of the pancreas as well as from that of functional
PETs [57–61]. Moreover, the two genetic phenotypes also
show correlation with ploidy status: high-FAL tumors are
aneuploid, while low-FAL neoplasms are diploid. When
utilized in conjunction with the Ki-67 cellular prolifera-
tion index, ploidy status provides powerful, independent
statistically significant information that predicts long-
term survival, even among metastatic cases [57]. It is likely
that the eventual separation of PETs into distinct clinical
and pathological groups will facilitate an even more pre-
cise delineation of PET prognosis, histopathology, and
carcinogenesis.
More recently, the study of sex chromosome abnormali-
ties in PETs by both microsatellite and FISH analysis iden-
tified different frequencies of loss and gain of sex
chromosomes in female and male cases [62]. The loss of a
sex chromosome significantly correlated with the pres-
ence of local invasion, metastasis, and higher prolifera-
tion status. Moreover, sex chromosome loss is
significantly associated with poor survival and increases
the risk of death by approximately two-fold [62].
Conclusion
The demonstration and realization that ductal adenocar-
cinoma has a distinct molecular fingerprint compared to
other nonductal or endocrine tumors has important im-
plications for the development of desperately needed ge-
netic screening tests, as well as for markers for early
diagnosis and prognosis. Unfortunately, the results of ge-
netic studies have not yet been translated into significant
clinical applications that show either diagnostic or thera-
peutic benefit for patients with pancreatic malignancies.
Much promise is held for the use of new technologies such
as expression profiling and proteome analysis.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/7
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